- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01221402
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis (ALPINE-SVG)
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial
Intermediate saphenous vein graft (SVG) lesions are common, have high rates of progression to severe lesions or occlusion, and are associated with high incidence of adverse clinical outcomes.
The ALPINE-SVG trial is a randomized-controlled trial of extended-release niacin vs. placebo in patients with intermediate saphenous vein graft lesions. The main hypothesis of the study is that compared to placebo, niacin administration will result in reduction in percent atheroma volume at 12-month follow-up angiography.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase II, single-center, double-blind trial that will randomize 138 prior CABG patients with an intermediate SVG lesion (30%-60% angiographic diameter stenosis) on clinically-indicated coronary angiography, and HDL-C<60 mg/dL to ER-niacin at a dose of 1500-2000 mg daily or matching placebo (containing 50 mg of niacin that can cause flushing but has no lipid lowering effect) for 12 months. All patients will receive a statin with goal LDL-C <70 mg/dL. Coronary angiography, intravascular ultrasonography (IVUS), and intravascular near-infrared intracoronary spectroscopy (NIRS), and optical coherence tomography (OCT) of the intermediate SVG lesion will be performed at enrollment and after 12 months in each patient, along with exercise stress testing at 1 month and 12 months, B-mode carotid ultrasound imaging at enrollment and after 6 and 12 months, reactive hyperemia peripheral arterial tonometry (RH-PAT) at enrollment and after 6 and 12 months, and with peripheral blood sampling performed at enrollment and at 1, 3, 6, 9 and 12 months, to determine whether compared to placebo, administration of ER-niacin will result in:
- Reduction of the percent atheroma volume (PAV) of the intermediate SVG lesion at 12-month follow-up IVUS imaging (primary endpoint)
- Reduction of total and normalized total intermediate SVG lesion atheroma volume, reduction of atheroma volume in the most diseased 10-mm subsegment of the target intermediate lesion, reduction of atheroma volume in the subsegment of the target intermediate lesion with lipid core plaque by NIRS, reduction of lipid core burden index as assessed by near-infrared intracoronary spectroscopy, increase in fibrous cap thickness and reduction in the prevalence and number of microchannels, in the presence and extent of necrotic lipid pool, plaque rupture, calcification, and thrombus, as assessed by optical coherence tomography, and reduction of angiographic intermediate SVG target lesion failure at 12-month follow-up SVG imaging (secondary endpoints)
- Increased exercise capacity and reduction in ischemia, as assessed by exercise stress testing between 1 and 12 months (secondary endpoint)
- Less increase in mean carotid intima-media thickness at 6 and 12 months (secondary endpoint)
- Greater increase in natural logarithmic scaled reactive hyperemia index (L_RHI) at 6 and 12 months (secondary endpoint)
- Greater increase in EPC-CFU/mL of peripheral blood from baseline to 1, 3, 6, and 12 months post enrollment (secondary endpoint)
- Reduction of major adverse cardiac events (defined as the composite of death, acute coronary syndrome, or coronary revascularization) during follow-up (secondary endpoint)
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75216
- VA North Texas Healthcare System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or greater
- Willing and able to give informed consent. The patients must be able to comply with study procedures and follow-up.
- Undergoing clinically-indicated coronary and SVG angiography
- Have an intermediate SVG lesion (defined as a lesion 30-60% angiographic diameter stenosis) without previous percutaneous intervention, amenable to examination with IVUS. The lesion should have no thrombus or ulceration and should not be considered responsible for the patient's clinical presentation and referral for graft angiography.
Exclusion Criteria:
- Known allergy to niacin
- History of statin-induced myopathy
- Positive pregnancy test or breast-feeding
- Coexisting conditions that limit life expectancy to less than 12 months or that could affect a patient's compliance with the protocol
- Uncontrolled fasting triglyceride levels ( 500 mg/dL)
- Fasting LDL-C >200 mg/dL
- Fasting HDL-C >60 mg/dL
- Poorly controlled diabetes (glycosylated hemoglobin levels 10%)
- Current active liver disease or hepatic dysfunction
- AST or ALT > 2x the upper limit of normal
- Uncontrolled hypothyroidism (Thyroid Stimulating Hormone >1.5 x upper limit of normal [ULN])
- Unexplained creatine kinase elevations (>3 x ULN)
- Recent history of acute gout
- Serum creatinine > 2.5 mg/dL
- HIV (due to potential anti-retroviral drug-interactions with niacin)
- Use of high-dose, antioxidant vitamins (vitamins C, E, or beta-carotene) that may interfere with the HDL-raising effect of niacin
- Severe peripheral arterial disease limiting vascular access
- Referral for cardiac catheterization by a physician who is an investigator in the present study.
- Symptoms consistent with moderate or greater severity of congestive heart failure (New York Heart Association - NYHA class III or IV) or whose most recent determination of left ventricular ejection fraction is <25%
- Uncontrolled hypertension, defined as either a resting diastolic blood pressure of ≥100 mmHg or a resting systolic blood pressure of ≥200 mmHg
- History of allergic reaction to iodine-based contrast agents
- Significant medical or psychological condition that, in the opinion of the investigator, may compromise the patient's safety or successful participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
|
Experimental: Extended-release niacin
|
Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change in percent atheroma volume at 12 months intravascular ultrasonography
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change in total and normalized total intermediate SVG lesion atheroma volume
Time Frame: 12 months
|
12 months
|
reduction of atheroma volume in the most diseased 10-mm subsegment of the target intermediate lesion
Time Frame: 12 months
|
12 months
|
reduction of atheroma volume in the subsegment of the target intermediate lesion with lipid core plaque by near-infrared spectroscopy
Time Frame: 12 months
|
12 months
|
lipid core burden index as assessed by near-infrared intracoronary spectroscopy
Time Frame: 12 months
|
12 months
|
increase in fibrous cap thickness and reduction in the prevalence and number of microchannels, in the presence and extent of necrotic lipid pool, plaque rupture, calcification, and thrombus, as assessed by optical coherence tomography
Time Frame: 12 months
|
12 months
|
angiographic intermediate SVG target lesion failure
Time Frame: 12 month
|
12 month
|
exercise capacity and ischemia, as assessed by exercise stress testing
Time Frame: 12 months
|
12 months
|
carotid intima-media thickness
Time Frame: 6 and 12 months
|
6 and 12 months
|
reactive hyperemia index
Time Frame: 12 months
|
12 months
|
EPC-CFU/mL of peripheral blood
Time Frame: 12 months
|
12 months
|
major adverse cardiac events (defined as the composite of death, acute coronary syndrome, or coronary revascularization)
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Emmanouil S Brilakis, MD, PhD, North Texas Veterans Healthcare System
Publications and helpful links
General Publications
- Kotsia AP, Rangan BV, Christopoulos G, Coleman A, Roesle M, Cipher D, de Lemos JA, McGuire DK, Packer M, Banerjee S, Brilakis ES. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. J Invasive Cardiol. 2015 Oct;27(10):E204-10.
- Guerra A, Rangan BV, Coleman A, Xu H, Kotsia A, Christopoulos G, Sosa A, Chao H, Han H, Abdurrahim G, Roesle M, de Lemos JA, McGuire DK, Packer M, Banerjee S, Brilakis ES. Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. J Invasive Cardiol. 2015 Dec;27(12):555-60.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Vitamins
- Vitamin B Complex
- Niacin
Other Study ID Numbers
- 10-029
- R01HL102442 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis
-
Lumen TherapeuticsTerminated
-
Catholic University of the Sacred HeartCompletedSaphenous Vein Graft Disease
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
-
Region Örebro CountyKarlstad Central HospitalEnrolling by invitationCoronary Artery Bypass | Percutaneous Coronary Intervention | Saphenous VeinSweden
-
Minneapolis Heart Institute FoundationRegeneron PharmaceuticalsTerminatedSaphenous Vein Graft AtherosclerosisUnited States
-
Boston Scientific CorporationCompletedSymptomatic Ischemic Saphenous Vein Graft DiseaseUnited States, Canada
-
Kips Bay Medical, Inc.UnknownAtherosclerosis of Autologous Vein Coronary Artery Bypass Graft(s)United States, United Kingdom, Czech Republic, Netherlands, France, Italy, Switzerland
-
Boca Raton Regional HospitalPfizerCompletedSaphenous Vein Graft DiseaseCanada, United States
-
Institute of Cardiology, Warsaw, PolandUnknownStenosis in Saphenous Vein Graft, Drug Eluting StentPoland
-
Tianjin Chest HospitalUnknownPercutaneous Coronary Intervention | Saphenous Vein Graft Disease | Major Adverse Cardiovascular Events | Virtual Histology Intravascular UltrasoundChina
Clinical Trials on extended-release niacin (Niaspan)
-
Brigham and Women's HospitalTerminatedInflammation | Cardiovascular Disease | Atherosclerosis | DialysisUnited States
-
University of PennsylvaniaCompletedHealthy VolunteersUnited States
-
University of HawaiiUnited States Department of DefenseCompletedHIV Infections | Dyslipidemia | Endothelial DysfunctionUnited States
-
University of MiamiTerminatedDiabetes Mellitus, Type 2 | Kidney Failure, Chronic | HyperlipidemiaUnited States
-
University of LeipzigCompletedCoronary Disease | HypolipoproteinemiaGermany
-
Cortria CorporationPPD; Pharmena North AmericaCompleted
-
Henry Ford Health SystemCompletedIschemic StrokeUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular DiseaseUnited States
-
Axio Research. LLCNational Heart, Lung, and Blood Institute (NHLBI); AbbottTerminatedMyocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis | Cerebrovascular AccidentUnited States, Canada
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Artery Disease | Atherosclerosis | Carotid Artery DiseasesUnited States, Canada